Report cover image

Non-Alcoholic Steatohepatitis (NASH) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update

Publisher GlobalData
Published Mar 27, 2023
Length 546 Pages
SKU # GBDT17909492

Description

Non-Alcoholic Steatohepatitis (NASH) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update


Summary

GlobalData's clinical trial report, “Non-Alcoholic Steatohepatitis (NASH) Clinical Trial Analysis by Trial Phase, Trial Status, Trial Counts, End Points, Status, Sponsor Type and Top Countries, 2023 Update provides an overview of Non-Alcoholic Steatohepatitis (NASH) Clinical trials scenario. This report provides top line data relating to the clinical trials on Non-Alcoholic Steatohepatitis (NASH). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma - Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy
  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

546 Pages
  • Report Guidance
  • GlobalData Clinical Trials Report Coverage
    • Figure 1: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region (%), 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Region, 2023*
    • Clinical Trials and Average Enrollment by Country
    • Figure 9: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2023*
    • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, G7 Countries (%), 2023*
    • Figure 10: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Phase, 2023*
    • Figure 11: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2023*
    • Figure 12: Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2023*
    • Proportion of Non-Alcoholic Steatohepatitis (NASH) to Gastrointestinal Clinical Trials, E7 Countries (%), 2023*
    • Figure 13: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Phase, 2023*
    • Figure 14: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2023*
    • Figure 15: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase (%), 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Phase, 2023*
    • In Progress Trials by Phase
    • Figure 17: Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics, Global, Clinical Trials by Trial Status, 2023*
    • Figure 18: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, by End Point Status, 2023*
    • Figure 19: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018-2022
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2018- 2022
    • Figure 20: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2023*
    • Figure 21: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Key Sponsors, 2023*
    • Top Companies Participating in Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials
    • Figure 23: Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023*
    • Non-Alcoholic Steatohepatitis (NASH) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2023*
  • Clinical Trial Profile Snapshots
    • Abbreviations
    • Definitions
    • Research Methodology
    • Secondary Research
    • About GlobalData
    • Contact Us
    • Disclaimer
  • Source

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us